Pharmafile Logo

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation strategies in drug development, the true value of ECAs remains a topic of considerable discussion. As the industry grapples with the integration of real-world evidence (RWE) in drug development and commercialization, understanding when and how ECAs successfully contribute to regulatory, health technology assessment (HTA), and clinical decision-making has become increasingly important.

ECA webinar image

Speakers:

Alexandra Sosinksy, ScM, Senior Director, Genesis Research Group, Hoboken, NJ, USA

Frank-Ulrich Fricke, PhD, Dean, Technische Hochschule Nürnberg and Arbitration Board on Drug Prices, Nuremberg, Germany

Mira Pavlovic, MD, Director, Centre Sabouraud, Saint-Louis Hospital, Paris, France and Lisbon University, Lisbon, Portugal

Description

In this webinar, speakers offering diverse stakeholders’ perspectives will critically examine the value of ECAs by framing their investments (costs, data access, development timelines, and stakeholder engagement) versus the potential payoff (faster approvals, smaller or fewer randomized trials, stronger contextual evidence for single-arm trials, and enhanced confidence in the totality of the evidence). Speakers will share their wide-ranging experience with ECA design and evaluation as well as their forward-looking view on the role of ECAs in the mandatory European Union (EU) HTA Joint Clinical Assessment (JCA) of oncology and advanced therapy drugs.

Attendees will leave with a clearer understanding of the conditions under which ECAs are most likely to deliver return on investment (ROI) as part of a complete evidence package, including insights into HTA and regulatory variability and future opportunities like the evolving EU JCA landscape.

Learning Objectives

  • Articulate key considerations for investing in ECAs across regulatory and HTA environments including data quality, cost, and potential for expedited decision- making.
  • Examine variability in ECA acceptance and identify conditions in which ECAs meaningfully impact payer, regulatory and clinical decision-making.
  • Draw learnings from shared examples and experience to maximize ROI of ECAs, and anticipate how evolving policies, such as EU JCA, may affect future evidence planning.

 

RESERVE YOUR PLACE OR REGISTER TO RECEIVE THE RECORDING

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication

We are pleased to share that The Evidence Base have carried out a 'deep dive' into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights...

Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online

Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...

Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

Genesis Research Group unveils enhanced US market access data analytics

Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...

Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program

Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...

Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’

ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...

How does Genesis Research Group ‘Innovate differently’?

New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...